Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1/2 1Phase 1 1

Status

Recruiting 3Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 5Recurrence 3Neoplasms 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Ovarian Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Cytokine Release Syndrome 1Craniopharyngioma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced Liver Cancers 1

Interventions

Cyclophosphamide 23venetoclax 17Dexamethasone 16pembrolizumab 15fludarabine 15Cytarabine 13pomalidomide 8Rituximab 8Gemcitabine 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7selinexor 6Paclitaxel 6Injections 6Immunotherapy, Adoptive 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Oxaliplatin 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Recurrence × tocilizumab × Clear all
NCT05533775 2026-06-03

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting
65 enrolled

Recurrence

NCT05927571 2026-06-03

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Genentech, Inc.

Phase 1 Recruiting
120 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06251076 2025-12-10

Plan Development for Giving Teclistamab in the Outpatient Setting

University Health Network, Toronto

Phase 4 Recruiting
15 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡